Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011460 | 0.90 | GRM5 (0.59) | GRM5ADRA1DFFAR1BRD4 | |
| SCHEMBL2009340 | 0.88 | GRM5 (0.46) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2009910 | 0.88 | GRM5 (0.47) | GRM5KCNH2ADRA1D | |
| SCHEMBL2009047 | 0.87 | GRM5 (0.52) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2013405 | 0.81 | GRM5 (0.50) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2015200 | 0.80 | GRM5 (0.42) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2009210 | 0.80 | LMNA (0.50) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL5038553 | 0.79 | GRM5 (0.44) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2010073 | 0.79 | GRM5 (0.43) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2009407 | 0.78 | GRM5 (0.56) | GRM5FFAR1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964620-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1831193-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20090018171-A1 | IMIDAZOLE DERIVATIVES | BUETTELMANN BERND | 2009-01-15 | — | — | US | disclosed |
| US-7452909-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20050054686-A1 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054686-A1 | Imidazole derivatives | CHRM2, CHRM1, ARG1 | GRM5 758/4885KCNH2 418/4885ADRB3 551/4885 |
| US-20090018171-A1 | IMIDAZOLE DERIVATIVES | CHRM2, CHRM1, ARG1 | GRM5 758/4885KCNH2 418/4885ADRB3 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.